Avet Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials

Avet Pharmaceuticals Inc. announced the immediate availability of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. The new product launch represents Avet’s first entry into the injectable generic market segment and serves as a lead product for its growing oncology product franchise. According to IMS data for the twelve months ended June 2012, the U.S. market for Irinotecan approximated $28 million.
Download Press Release